AMA continues push for MU changes

The American Medical Association (AMA) is pleased with the Meaningful Use Stage 2 extension but continues to advocate for more flexibility to keep the program going.

"The American Medical Association is pleased that the Centers for Medicare & Medicaid Services (CMS) has decided to extend the deadline for eligible providers to attest to Meaningful Use, but is concerned that the program will still face low participation rates without substantial changes to its rigid requirements," said President-Elect Steven Stack, MD.

"Only 24 percent of physicians have attested to Meaningful Use for 2014 as of the beginning of February. The deadline extension underscores that the Meaningful Use program is not working and that policymakers need to act on our recommendations to make it more flexible, remove the measures that physicians are having the most difficulty in meeting and revamp the certification program so that electronic health record vendors can innovate to create products that better serve patients and physicians."

AMA's recommendations stem from its Meaningful Use blueprint issued last fall which focuses on more flexibility, better alignment of quality measure requirements and restructured EHR certification.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.